Evaluation of Fosaprepitant's Effect on Drug Metabolism in Sarcoma Patients Receiving Ifosfamide-based Multi-day Chemotherapy Regimen

Trial Profile

Evaluation of Fosaprepitant's Effect on Drug Metabolism in Sarcoma Patients Receiving Ifosfamide-based Multi-day Chemotherapy Regimen

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Apr 2016

At a glance

  • Drugs Fosaprepitant (Primary) ; Ifosfamide (Primary) ; Antineoplastics
  • Indications Chemotherapy-induced nausea and vomiting; Sarcoma
  • Focus Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 11 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 02 Jun 2015 Primary endpoint has been met (Area under the drug concentration-time curve Ifosfamide AUC), according to an abstract presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2015 Primary endpoint has been met (Complete Response), according to an abstract presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top